Weekly Analysts’ Ratings Updates for Moderna (MRNA)

Moderna (NASDAQ: MRNA) has recently received a number of price target changes and ratings updates:

• 7/21/2026 – Moderna had its price target raised by The Goldman Sachs Group, Inc. from $49.00 to $67.00. They now have a “neutral” rating on the stock.
• 7/20/2026 – Moderna had its “underperform” rating reaffirmed by Wolfe Research. They now have a $25.00 price target on the stock.
• 7/8/2026 – Moderna had its price target raised by Morgan Stanley from $33.00 to $39.00. They now have an “equal weight” rating on the stock.
• 7/7/2026 – Moderna had its price target raised by Royal Bank Of Canada from $38.00 to $45.00. They now have a “sector perform” rating on the stock.
• 7/7/2026 – Moderna had its price target raised by Bank of America Corporation from $34.00 to $38.00. They now have an “underperform” rating on the stock.
• 6/26/2026 – Moderna had its price target raised by Piper Sandler from $69.00 to $77.00. They now have an “overweight” rating on the stock.
• 6/18/2026 – Moderna had its “hold” rating reaffirmed by Jefferies Financial Group Inc..
• 6/12/2026 – Moderna had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/8/2026 – Moderna had its price target raised by Bank of America Corporation from $32.00 to $34.00. They now have an “underperform” rating on the stock.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the transaction, the insider directly owned 67,468 shares in the company, valued at $3,373,400. This trade represents a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Noubar Afeyan sold 9,263 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $46.84, for a total value of $433,878.92. Following the completion of the sale, the director directly owned 3,924 shares of the company’s stock, valued at $183,800.16. This represents a 70.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 125,088 shares of company stock valued at $6,193,713. Corporate insiders own 10.80% of the company’s stock.

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.